2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 192

Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
Abstract Number: 193

Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects
Abstract Number: 194

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Abstract Number: 195

Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Abstract Number: 196

Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study
Abstract Number: 197

Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study
Abstract Number: 198

A Phase 2 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout and Moderate Renal Impairment
Abstract Number: 199

A Phase 3 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout
Abstract Number: 200

The Safety and Efficacy of Benzbromarone in Gout in Aotearoa New Zealand
Abstract Number: 201

Allopurinol Reduces the Risk of Myocardial Infarction (MI) in the Elderly: A Study of Medicare Claims
Abstract Number: 202

Allopurinol Use and the Risk of Ventricular Tachycardia in the US Elderly: A Study of Medicare Claims Data
Abstract Number: 203

Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study
Abstract Number: 204

The Safety and Efficacy of Allopurinol Dose Escalation in People with Gout, a Randomised Controlled Trial
Abstract Number: 205

Serum Uric Acid Lowering Treatment Appears Unnecessary during Hemodialysis
Abstract Number: 206

Renal Safety of Lesinurad: A Pooled Analysis of Phase III and Extension Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].